{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:11:40Z","timestamp":1790687500224,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40265-023-01945-x","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:01:57Z","timestamp":1696399317000},"page":"1439-1445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Talquetamab: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"issue":"5","key":"1945_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41571-023-00735-4","volume":"20","author":"K Nath","year":"2023","unstructured":"Nath K, Costa BA, Mailankody S. GPRC5D as a novel immunotherapeutic target in multiple myeloma. Nat Rev Clin Oncol. 2023;20(5):281\u20132.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1945_CR2","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196\u2013215.","journal-title":"Blood Adv"},{"key":"1945_CR3","doi-asserted-by":"publisher","unstructured":"Swan D, Murphy P, Glavey S, et al. Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety. Cancers. 2023;15(6). https:\/\/doi.org\/10.3390\/cancers15061819.","DOI":"10.3390\/cancers15061819"},{"issue":"S2","key":"1945_CR4","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/ajh.26628","volume":"98","author":"G Ravi","year":"2023","unstructured":"Ravi G, Costa LJ. Bispecific T-cell engagers for treatment of multiple myeloma. Am J Hematol. 2023;98(S2):S13\u201321.","journal-title":"Am J Hematol"},{"issue":"3","key":"1945_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood.2022018157","volume":"141","author":"JL Harousseau","year":"2023","unstructured":"Harousseau JL, Mohty M. Sequencing anti-BCMA therapies in myeloma. Blood. 2023;141(3):211\u20132.","journal-title":"Blood"},{"key":"1945_CR6","unstructured":"Janssen Biotech Inc. Talquetamab (talquetamab-tgvs): US prescribing information. 2023. https:\/\/www.talvey.com\/. Accessed 11 Aug 2023."},{"key":"1945_CR7","unstructured":"European Medicines Agency. Talquetamab: EU prescribing information. 2023. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230821160195\/anx_160195_en.pdf. Accessed 28 Aug 2023."},{"key":"1945_CR8","unstructured":"Janssen. U.S. FDA approves TALVEY\u2122 (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma [media release]. 10 Aug 2023. https:\/\/www.jnj.com\/."},{"key":"1945_CR9","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma [media release]. 8 Aug 2023. https:\/\/www.fda.gov\/."},{"key":"1945_CR10","unstructured":"Janssen. European Commission approves TALVEY\u00ae (talquetamab), Janssen\u2019s novel bispecific therapy for the treatment of patients with relapsed and refractory multiple myeloma [media release]. 22 Aug 2023. https:\/\/www.janssen.com\/."},{"key":"1945_CR11","unstructured":"Genmab A\/S. Genmab enters broad collaboration with Janssen Biotech, Inc. for DuoBody platform [media release]. 12 Jul 2012. https:\/\/www.genmab.com."},{"key":"1945_CR12","unstructured":"Genmab A\/S. Genmab announces expansion of DuoBody platform collaboration with Janssen Biotech, Inc. [media release]. 4 Dec 2013. https:\/\/www.genmab.com."},{"issue":"15","key":"1945_CR13","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232\u201343.","journal-title":"Blood"},{"issue":"24","key":"1945_CR14","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"16 Suppl","key":"1945_CR15","doi-asserted-by":"publisher","first-page":"8041","DOI":"10.1200\/JCO.2023.41.16_suppl.8041","volume":"41","author":"X Ma","year":"2023","unstructured":"Ma X, Gong J, Zhou J, et al. Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): analyses from MonumenTAL-1 [abstract no. 8041]. J Clin Oncol. 2023;41(16 Suppl):8041.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"1945_CR16","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, Touzeau C, Minnema MC, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM) [abstract no. 8036 plus presentation]. J Clin Oncol. 2023;41(16 Suppl):8036.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"1945_CR17","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","volume":"41","author":"BR Dholaria","year":"2023","unstructured":"Dholaria BR, Weisel K, Mateos MV, et al. Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results [abstract no. 8003]. J Clin Oncol. 2023;41(16 Suppl):8003.","journal-title":"J Clin Oncol"},{"key":"1945_CR18","unstructured":"Janssen. Janssen presents longer-term talquetamab follow-up data showing overall response rates of more than 70 percent in heavily pretreated patients with multiple myeloma [media release]. 3 June 2023. https:\/\/www.janssen.com."},{"issue":"16 Suppl","key":"1945_CR19","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","volume":"41","author":"YC Cohen","year":"2023","unstructured":"Cohen YC, Morillo D, Gatt ME, et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) [abstract no. 8002 plus presentation]. J Clin Oncol. 2023;41(16 Suppl):8002.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01945-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:07:03Z","timestamp":1697540823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01945-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":19,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1945"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01945-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"4 October 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}